2026 SoLA

Nutritional modulation of metabolic enzymes and epigenetic approaches for cardiometabolic health

Predicting drug-food interactions using AI

Shared metabolic switches in obesity treatment: from intermittent fasting to GLP1 based therapy

CVD risk prediction in lipid guidelines

CVD risk prediction in diabetes guidelines

CVD risk prediction in hypertension guidelines

CVD risk prediction in the context of CKM health

HDL-C in the guidelines: where do we stand today?

HDL-C is cardioprotective - higher HDL-C reduces ASCVD risk

Extremely high HDL-C may be harmful - function matters more than quantity

Appropriate statin therapy for low- to moderate-risk patients ("The earlier, the better; the longer, the better.")

CKD and lipid management: when guidelines differ, what should we do?

Updated digital technology for atherosclerosis management

Multi-modality intracoronary imaging for characterizing atherosclerosis

AI for cardiovascular image in CT

Beyond the Statin, ROSUZET; start early, switch now

Ultra–low-dose triple FDC in hypertension: a new initial treatment paradigm and the patients who benefit

Association between cumulative LDL-C exposure during young adulthood and middle age and risk of cardiovascular events

MASLD as a cardiovascular risk enhancer in primary prevention

Lipid-lowering therapy for primary prevention in the elderly

Sex differences in metabolic syndrome and heart

Uncovering FPR2 as a determinant of sex differences in liver fibrosis

Sex-dependent microbe-metabolite interactions in cardiometabolic diseases